Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pill (fiercebiotech.com)

Three years after Robert Hoffman sold XinThera to Gilead, the veteran Pfizer chemist has unveiled his latest venture. | Three years after Robert Hoffman sold XinThera to Gilead, the veteran Pfizer che...